CHICAGO, June 2 (Reuters) - Investors searching for the next major artificial intelligence winner may be increasingly turning their attention from chatbots and software to a far larger prize: healthcare.
‍

That shift was on display this week as Tempus AI (Nasdaq: TEM) used the American Society of Clinical Oncology (ASCO) annual meeting to unveil dozens of studies demonstrating how artificial intelligence and one of the world's largest clinical and molecular datasets can help doctors make faster, more accurate treatment decisions for cancer patients.
‍

The company's 37 accepted research abstracts represented a record presence at ASCO and underscored a vision that extends well beyond cancer diagnostics. Tempus is building what many investors view as the foundational data layer for precision medicine—a platform designed to connect genomic sequencing, pathology reports, imaging data, physician notes and real-world patient outcomes into a single system capable of guiding care.
‍

The stakes are enormous.
‍

Despite decades of advances in medicine, physicians still frequently make treatment decisions with incomplete information. Cancer alone affects nearly 20 million people globally each year, while healthcare systems spend trillions of dollars annually treating patients whose outcomes often depend on finding the right therapy quickly. Delays, misdiagnoses and ineffective treatments contribute to hundreds of billions of dollars in avoidable costs.
‍

Tempus believes artificial intelligence can change that equation.
‍

Rather than relying solely on traditional diagnostic methods, the company's platform analyzes vast amounts of patient data to identify patterns that may not be visible to physicians. In practice, that could mean helping oncologists identify which patients are most likely to respond to a particular drug, detecting disease earlier, matching patients to clinical trials more efficiently or reducing costly trial-and-error treatment approaches.
‍

For investors, the appeal lies in the scale of the opportunity.
‍

Healthcare represents nearly 20% of U.S. GDP, yet much of the industry's decision-making infrastructure remains fragmented and analog. Supporters of Tempus argue that if artificial intelligence can improve even a small fraction of clinical decisions, the economic impact could be measured in hundreds of billions of dollars annually.
‍

That helps explain why Wall Street increasingly views Tempus as more than a diagnostic testing company.
‍

Instead, bulls see similarities to businesses that became indispensable data infrastructure providers in other industries. Just as Bloomberg became a critical information platform for finance, Tempus is attempting to become an essential intelligence platform for healthcare—one that grows more valuable as additional patient data, clinical outcomes and pharmaceutical research flow through its network.
‍

The company has already amassed one of the largest libraries of multimodal healthcare data in the industry, creating a competitive advantage that could become increasingly difficult for rivals to replicate. Every additional patient record, molecular profile and treatment outcome strengthens the predictive power of its algorithms, creating a flywheel effect that investors believe could accelerate over time.
‍

The pharmaceutical industry may ultimately become one of the largest beneficiaries.
‍

Drug developers spend billions of dollars bringing new therapies to market, yet clinical trial failure rates remain stubbornly high. By helping identify appropriate patient populations and predict therapeutic responses, AI-powered platforms such as Tempus could improve development efficiency while shortening timelines for potentially life-saving medicines.
‍

Those possibilities have fueled enthusiasm among both institutional and retail investors, helping drive strong gains in Tempus shares since the company's public debut.
‍

The story has also attracted attention because venture capitalist Paul Pelosi, husband of former House Speaker Nancy Pelosi, holds a substantial stake in the company.

Pelosi's investment activity is closely monitored by market participants due to the strong performance of several high-profile investments over the years.
‍

Still, Tempus' long-term investment case ultimately rests less on political intrigue than on whether its technology can meaningfully improve patient outcomes.
‍

If artificial intelligence succeeds in helping physicians detect diseases earlier, select more effective treatments and reduce unnecessary healthcare spending, investors may eventually view today's oncology-focused platform as the early foundation of something much larger: a healthcare intelligence network capable of reshaping how medicine is practiced.
‍

For now, ASCO offered a glimpse of that vision—and a reminder that some of AI's most valuable applications may emerge not from generating text, but from helping save lives.